Cargando…

Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients

The aim of this study was to evaluate the impact of white blood cell (WBC) counts at presentation on the achievement of deep molecular response. A total of 362 newly diagnosed chronic-phase chronic myeloid leukemia patients (CML-CP) receiving 400 mg/day imatinib were serially monitored for a median...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Ya-Zhen, Jiang, Qian, Jiang, Hao, Lai, Yue-Yun, Zhu, Hong-Hu, Liu, Yan-Rong, Jiang, Bin, Huang, Xiao-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718283/ https://www.ncbi.nlm.nih.gov/pubmed/26765457 http://dx.doi.org/10.1097/MD.0000000000002486

Ejemplares similares

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China
por: Deng, Mengyue, et al.
Publicado: (2020)

Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
por: Xu, Fang, et al.
Publicado: (2017)

Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
por: Yu, Lu, et al.
Publicado: (2019)

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
por: Huang, Lanshan, et al.
Publicado: (2016)

Pulmonary hypertension in patients with chronic myeloid leukemia
por: Song, Ik-Chan, et al.
Publicado: (2021)

Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study
por: Mao, Xia-Li, et al.
Publicado: (2021)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report
por: Jiang, Qu, et al.
Publicado: (2017)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report
por: Li, Xiang, et al.
Publicado: (2020)

Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study
por: Merdin, Alparslan, et al.
Publicado: (2021)

Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia
por: Dai, Qingkai, et al.
Publicado: (2021)

Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report
por: Gao, Lu, et al.
Publicado: (2021)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia
por: Huang, Yuan-Mao, et al.
Publicado: (2021)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review
por: Li, Xiaoning, et al.
Publicado: (2021)

Copper-associated hepatitis in a patient with chronic myeloid leukemia following hematopoietic stem cell transplantation: A case report
por: Lee, Ching-Fen, et al.
Publicado: (2017)

Clinical insights into hematologic malignancies and comparative analysis of molecular signatures of acute myeloid leukemia in different ethnicities using an artificial intelligence offering
por: Snowdon, Jane L., et al.
Publicado: (2021)

Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: A case report and literature review
por: Gao, Yang, et al.
Publicado: (2023)

Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report
por: Lee, Chang-Hoon, et al.
Publicado: (2020)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience
por: Saleem, Umera, et al.
Publicado: (2020)

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era
por: Wei, Min, et al.
Publicado: (2021)

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
por: Guenounou, Sarah, et al.
Publicado: (2016)

Case Report of acute myeloid leukemia with “WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19” developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy
por: Zhu, Huan, et al.
Publicado: (2020)

Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: A case report
por: Wei, Wei, et al.
Publicado: (2020)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia
por: Mulu Fentie, Atalay, et al.
Publicado: (2019)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia
por: Li, Hui-Fang, et al.
Publicado: (2016)

A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study
por: Wang, Xinye, et al.
Publicado: (2020)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Acute myeloid leukemia presenting as erythema nodosum: A case report
por: Xu, Xiaohan, et al.
Publicado: (2017)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients
por: Ding, Ting, et al.
Publicado: (2019)

Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center
por: Liu, Zhigang, et al.
Publicado: (2021)

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
por: Michel, Christian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9g9fcdrsn85cu0high3luqkll4